SAB Biotherapeutics (NASDAQ:SABS) Stock Rating Reaffirmed by HC Wainwright
HC Wainwright reaffirmed their buy rating on shares of SAB Biotherapeutics (NASDAQ:SABS – Free Report) in a research note released on Monday morning, Benzinga reports. HC Wainwright currently has a $10.00 price objective on the stock, up from their prior price objective of $1.00. HC Wainwright also issued estimates for SAB Biotherapeutics’ Q4 2023 earnings […]
More Stories
GGL Resources (CVE:GGL) Shares Up 42.9% – Should You Buy?
Shares of GGL Resources Corp. (CVE:GGL – Get Free Report) were up 42.9% during trading on Monday . The company...
Sunrise Resources (LON:SRES) Shares Down 6.7% – Time to Sell?
Sunrise Resources plc (LON:SRES – Get Free Report)’s share price dropped 6.7% during mid-day trading on Monday . The stock...
Refined Metals (OTCMKTS:CADMF) Shares Up 16.4% – What’s Next?
Refined Metals Corp. (OTCMKTS:CADMF – Get Free Report) shot up 16.4% during mid-day trading on Monday . The company traded...
Cymat Technologies (CVE:CYM) Shares Up 8.7% – Here’s Why
Cymat Technologies Ltd. (CVE:CYM – Get Free Report) shares rose 8.7% during mid-day trading on Monday . The company traded...
Eutelsat Group (OTCMKTS:EUTLF) Sees Large Growth in Short Interest
Eutelsat Group (OTCMKTS:EUTLF – Get Free Report) saw a large increase in short interest during the month of December. As...
iShares U.S. Tech Breakthrough Multisector ETF (NYSEARCA:TECB) Shares Down 1.1% – Time to Sell?
iShares U.S. Tech Breakthrough Multisector ETF (NYSEARCA:TECB – Get Free Report)’s share price fell 1.1% during mid-day trading on Monday...